Between Rocks and Hard Places: The Southeast Asian Pharmaceutical Industry at a Juncture - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Between Rocks and Hard Places: The Southeast Asian Pharmaceutical Industry at a Juncture

Pharmaceutical Technology

In the Philippines, too, reform is on the way and the business conditions are evolving fast. As a local medium-size player, you stand a chance to gain benefits from these reshufflings, as your local knowledge will always prime. Indeed, companies like United Laboratories, a leader in the Philippines, have grown from modest players to giants with increasingly global outlooks. And, all these companies conserve the benefits of market recognition and local knowledge that are indispensable to succeed in challenging markets such as Southeast Asia's.

The changing shape and business conditions in the Southeast Asian pharmaceutical industry should in turn open avenues of cooperation between US or European companies and Asian players. Amongst similar companies by size and profiles, there are plenty of synergies to be developed. With local companies often being able to tap into consumer pools ranging from 25 to 220 million people for one country, and up to potentially 520 million consumers across the region, market prospects are appealing, even when considering the low disposable-income levels. Should a western company be the holder of an innovative technology that can be easily transposed in Asia, and many success stories could blossom and thrive. The ethos and business abilities of local players, from the leaders through to the challengers, are very convincing. Their faith in the market is genuine and their will to succeed is fundamental. Like-minded business people from across the world always find subjects of common interests. At the time of over-focus on China and India, it is well worth to step back, take some prospective, and see the opportunities waiting to be realized in Indonesia, Malaysia, Thailand, the Philippines, and Singapore.

This report was prepared by Executive Country Reviews. Authors are Gilles Valentin
Emmanuelle Berthemet
Marco Parigi
Amicie de Bodinat
and Yaz Yazicioglu


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here